Assessing the value of CAN-gene mutations using MALDI-TOF MS by Kohler, Corina et al.
ORIGINAL PAPER
Assessing the value of CAN-gene mutations
using MALDI-TOF MS
Corina Kohler • Bjo¨rn Tavelin • Alex Xiu-Cheng Fan •
Ramin Radpour • Zeinab Barekati • Fabio Levi •
Xiao Yan Zhong • Per Lenner • Paolo Toniolo
Received: 20 April 2011 / Accepted: 26 May 2011 / Published online: 21 June 2011
 Springer-Verlag 2011
Abstract
Purpose To identify cancer-linked genes, Sjo¨blom et al.
and Wood et al. performed a genome-wide mutation
screening in human breast and colorectal cancers. 140
CAN-genes were found in breast cancer, which in turn
contained overall 334 mutations. These mutations could
prove useful for diagnostic and therapeutic purposes.
Methods We used a MALDI-TOF MS 40-plex assay for
testing 40 loci within 21 high-ranking breast cancer CAN-
genes. To confirm mutations, we performed single-plex
assays and sequencing.
Results In general, the mutation rate of the analyzed loci
in our sample cohort was very low. No mutation from the
40 loci analyzed could be found in the 6 cell lines. In tissue
samples, a single breast cancer tissue sample showed het-
erozygosity at locus c.5834G[A within the ZFYVE26
gene (Zinc finger FYVE domain-containing gene 26).
Conclusions Sjo¨blom et al./Wood et al. already showed
that the vast majority of CAN-genes are mutated at very
low frequency. Due to the fact that we only found one
mutation in our cohort, we therefore assume that at the
selected loci, mutations might be low-frequency events and
therefore, more rarely detectable. However, further evalu-
ation of the CAN-gene mutations in larger cohorts should
be the aim of further studies.
Keywords Breast cancer  CAN-genes 
MALDI-TOF MS  Multiplex assay
Background
The decoding of the human genetic code at the beginning
of the twenty-first century officially heralded the age of
genomics and laid a solid foundation for the future
molecular research (Collins and McKusick 2001; Venter
et al. 2001). Casting a retrospective glance at the last few
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years, the achievements of the human genome project
accounted strongly for the development in the research of
genetically determined diseases. Identifying disease-related
genes and understanding their involvement in pathogenesis
is one of the fundamental goals currently pursued by the
scientists from different fields (The Wellcome Trust Case
Control Consortium 2007; Nessling et al. 2005).
Because cancer is one of the leading causes of death
worldwide and has a primarily genetic determination,
cancer research now dedicates itself to the search for genes
that are involved in carcinogenesis. It is already known that
mutations affecting some oncogenes and tumor suppressor
genes, such as TP53 and BRCA1/2, are linked with an
increased cancer risk (Soussi and Lozano 2005; Walsh
et al. 2006). However, to date, there are only a few genes
for which the existence of such a linkage is scientifically
confirmed.
For this reason, high-throughput mutation profiling
using large-scale sequencing approaches has been con-
ducted and numerous candidate genes have been identified.
Sjo¨blom et al. and Wood et al. conducted a sequencing-
based genome-wide mutation screening in human breast
and colorectal cancer with the aim of identifying genes
linked with these cancers (Sjoblom et al. 2006; Wood et al.
2007). By testing nearly every well-annotated gene in both
cancer types and by finally using stringent statistical cri-
teria, they identified 280 genes overall that were mutated at
a significant frequency, calling them candidate cancer
genes (CAN-genes). The discovery of these CAN-genes in
breast cancer could prove useful for diagnostic and thera-
peutic applications.
To evaluate the probable applicability of these CAN-genes
for clinical purposes, we used MALDI-TOF MS 40-plex assay
to test 40 single-nucleotide variants on 21 high-ranking CAN-
genes in 6 breast cancer cell lines and in tissues of 19 breast
cancer patients and 55 healthy controls.
Methods
Cell lines and culture conditions
MDA-MB-231, MCF-7, and HS578T were grown in
DMEM (high glucose with L-glutamine). BT549 and T47D
were cultured in RPMI 1640 medium, and SKBR3 was
grown in McCoy‘s 5A. All media were supplemented with
10% FCS and 1% penicillin–streptomycin. The cells were
maintained in a humid incubator at 37C with 5% CO2.
Study cohort
The study was performed at the Laboratory for Gyneco-
logical Oncology/Department of Biomedicine, Women’s
Hospital Basel and approved by the Ethical Committee of
the University of Umea˚. Patient information can be
obtained from Table 1.
DNA extraction
For DNA extraction from cell lines and paraffin-embedded
tissue samples, the High Pure PCR Template Preparation
Kit (Roche Diagnostics, Germany) was used according to
the manufacturer’s protocol. Before extraction, cells were
washed with 19 PBS. For patient samples, paraffin-
embedded tissue sections were pretreated as proposed in
the kit manual. The DNA was finally eluted in 100 ll
elution buffer and stored at -20C until further use. DNA
concentration was measured using a NanoDrop ND-1000
spectrophotometer (Biolab, Mulgrave, VIC, Australia).
Assay design for detection of CAN-gene mutations
Wood et al. defined 140 genes containing more than 334
mutations as CAN-genes for breast cancer using cancer
mutation prevalence (CaMP) score, which is calculated
based on the likelihood that the amount of mutations in any
gene is higher than those expected from a background
mutation rate. Of the 140 CAN-genes, we selected 21
genes containing 40 loci (Table 2). For the design of the
capture and the extension primers, the DNA sequences
containing the CAN-gene mutations were entered in the
software MassArray Assay Design version.3.1 (Sequenom,
San Diego, CA, USA). Information about sequences and
mass of capture and extension primers can be obtained
from Supplementary 1 (Table 1a).
Genotyping using MALDI-TOF MS
For SNP genotyping, the iPLEX Gold assay (Sequenom,
San Diego, CA, USA) was used. The assay consists of 3
Table 1 Clinical data of
patients
Patient data divided into two
subgroups according to
pathological tumour type. ER
positive, Estrogen receptor
positive, PR positive,
Progesterone receptor positive
Histological type Total no.
of patients
Age (years)
mean ± S.D.
(range)
Stage ER positive PR positive
1 2A 2B
Invasive ductal
carcinoma
14 49 ± 10.8 (28–63) 11 2 1 5 4
Medullary carcinoma 5 50 ± 7.9 (36–56) 1 4 0 0 0
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major steps: 1. Capture PCR (amplification of the amplicon
containing the locus of interest); 2. Shrimp alkaline phos-
phatase (SAP) treatment (removal of unincorporated
dNTPs); and 3. iPLEX reaction (Primer extension).
1. The Capture PCR was carried out in a 10 ll-PCR
volume containing 1 ll DNA (10 ng/ll), 1.625 mM
MgCl2, 500 lM dNTP mix, 0.5U Hotstart Taq DNA
polymerase (Quiagen), and primer mix (containing all
Table 2 First CAN-gene assay
Gene CCDS accession CaMP score Nucleotide (genomic) Nucleotide (cDNA) Amino acid (protein)
THBS3 NM_007112 3.5 g.chr1:151978713A[G c.2863A[G p.R955G
SP110 NM_004509 3.81 g.chr2:230907125T[C c.23T[C p.M8T
TLN1 NM_006289 2.98 g.chr9:35690282C[T (homozygous) c.6566C[T p.A2189V
ZNF646 NM_014699 3.06 g.chr16:30999156A[T c.4010A[T p.N1337I
TRIOBP NM_001039141 3.54 g.chr22:36443733A[T c.670A[T p.R224W
ZNF569 NM_152484 3.28 g.chr19:42609051C[G c.85C[G p.Q29E
XDH NM_000379 3.76 g.chr2:31500578C[G (homozygous) c.2371C[G p.R791G
VEPH1 NM_024621 5.34 g.chr3:158461684_158461683delAA c.2443_2444 delAA Fs
XDH NM_000379 3.76 g.chr2:31501422C[T c.2287C[T p.L763F
ZFYVE26 NM_015346 3.06 g.chr14:67302874G[A c.5834G[A p.R1945Q
ZNF569 NM_152484 3.28 g.chr19:42597140A[G c.260A[G p.E87G
TP53 NM_000546 55.19 g.chr17:7519167A[G (homozygous) c.488A[G p.Y163C
ZFP64 NM_199427 3.39 g.chr20:50134614G[C c.1827G[C p.K609 N
TP53 NM_000546 55.19 g.chr17:7520091C[G c.321C[G p.Y107X
TP53 NM_000546 55.19 g.chr17:7518335A[T (homozygous) IVS5-2A[T Sp
ZFYVE26 NM_015346 3.06 g.chr14:67321561C[A c.3491C[A p.A1164E
TMEM123 NM_052932 4.7 g.chr11:101777989A[C c.259A[C p.N87H
TRIOBP NM_001039141 3.54 g.chr22:36436328T[A c.515T[A p.V172E
VEPH1 NM_024621 5.34 g.chr3:158581776G[T c.998G[T p.S333I
TP53 NM_000546 55.19 g.chr17:7519095G[C IVS4 ? 1G[C Sp
TIMELESS NM_003920 2.96 g.chr12:55101032C[G c.3022C[G p.Q1008E
TP53 NM_000546 55.19 g.chr17:7517747C[T (homozygous) c.916C[T p.R306X
TP53 NM_000546 55.19 g.chr17:7517831C[T c.832C[T p.P278S
TLN1 NM_006289 2.98 g.chr9:35693800C[T c.6329C[T p.A2110 V
TG NM_003235 5.84 g.chr8:134030233C[G (homozygous) c.5264C[G p.P1755R
TP53 NM_000546 55.19 g.chr17:7518937C[T c.637C[T p.R213X
TMPRSS6 NM_153609 3.28 g.chr22:35810313G[A c.668G[A p.R223H
TECTA NM_005422 4.56 g.chr11:120504208T[A (homozygous) c.2312T[A p.I771N
TACC2 NM_206862 2.65 g.chr10:123834397C[G c.2392C[G p.L798V
TECTA NM_005422 4.56 g.chr11:120494285G[A c.851G[A p.R284H
TG NM_003235 5.84 g.chr8:133994534C[G c.4220C[G p.S1407X
TG NM_003235 5.84 g.chr8:133968052A[G (homozygous) c.1253A[G p.D418G
TDRD6 NM_001010870 2.69 g.chr6:46764550C[G c.726C[G p.F242L
TMEM123 NM_052932 4.7 g.chr11:101777516T[C c.509T[C p.M170T
TG NM_003235 5.84 g.chr8:134103511G[T c.6970G[T p.A2324S
TCF1 NM_000545 3.48 g.chr12:119900103G[A c.1721G[A p.S574N
SLC6A3 NM_001044 3.66 g.chr5:1456172A[C c.1632A[C p.R544S
TECTA NM_005422 4.56 g.chr11:120505627delA c.2438delA Fs
TDRD6 NM_001010870 2.69 g.chr6:46769240G[C c.5416G[C p.E1806Q
SULF2 NM_018837 3.84 g.chr20:45728625T[C c.1591T[C p.Y531H
The table shows the genes analyzed in the MALDI-TOF MS 40-plex assay, the associated CCDS accession number, the cancer mutation
prevalence score (CaMP score), the nucleotide and genomic position, and the affected amino acid. To optimize the signal-to-noise ratio, the 40
CAN-gene positions have been divided into four mass groups indicated by the parting lines
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40 amplification primer pairs). PCR amplification was
performed using a Mastercycler gradient (Eppendorf,
Germany) under the following conditions: Preincuba-
tion at 94C for 15 min, followed by 45 cycles of 94C
for 20 s, 56C for 30 s, and 72C for 1 min, and a final
extension step at 72C for 3 min.
2. For the removal of unincorporated dNTPs, SAP
treatment using shrimp alkaline phosphatase (Seque-
nom) was performed at 37C for 40 min and 85C for
5 min, followed by a final cooling to 4C.
3. For the iPLEX reaction, a PCR cocktail mix was made
using iPLEX buffer (109), 0.4 ll iPLEX termination
mix, 0.08 ll iPLEX enzyme, and the primer mix
(consisting of all 40 extension primers). As there is an
inverse relationship between peak intensity and analyte
mass that influences the signal-to-noise ratio, a clas-
sification of different mass groups is required when
performing high-plex assays. To ensure an optimal
signal-to-noise ratio, we divided our assay into 4
different mass groups (7, 9.66, 10.33, and 14 lM). The
PCR was carried out in a Mastercycler gradient
(Eppendorf, Germany) using a 200-short-cycle pro-
gram consisting of two cycling loops. The first loop of
five cycles is located within a second loop of 40 cycles.
The PCR starts with a first denaturation at 94C for
30 s, followed by 40 cycles of denaturation at 94C for
5 s, primer annealing at 52C for 5 s, and extension at
80C for 5 s. Within these 40 cycles, the primer
annealing and extension step is repeated 5 times
resulting in a total of 200 cycles. After the 200 cycles,
a final extension is done at 72C for 3 min, and the
product is cooled down to 4C.
To optimize the mass spectrometric analysis, the iPLEX
reaction products were desalted using clean resin and then
dispensed on a 384-element SpectroCHIP bioarray by a
Nanodispenser (Sequenom). For measuring the assay
reproducibility, each sample was run in duplicate and
found mutation(s) were reconfirmed with single-plex assay
and sequencing. For the processing and analysis of the
iPLEX SpectroCHIP, the MassARRAY Compact system
and the MassARRAY Workstation software version 4.0
(Sequenom) were used.
Sequencing analysis
The PCR was carried out in 25 ll total volume containing
17.4 ll H2O, 2.5 ll 109 PCR buffer (Quiagen), 0.5 ll
dNTP mix (25 mM) (Quiagen), 1.25 ll of each primer,
0.1 ll Hotstart Taq (Quiagen), and 2 ll DNA. The PCR
was performed under the following conditions: initial
denaturation at 94C for 15 min, followed by 45 cycles at
94C for 20 s, 60C for 30 s, and 72C for 1 min, and a
final extension at 72C for 3 min. Removal of primers
and dNTPs was done using Exo1/SAP treatment. To
25 ll of the PCR, 0.3 ll Exo1, 0.6 ll Exo1 buffer (109)
(both Fermentas), 3 ll SAP (Sequenom), and 2.1 ll H2O
were added and incubated under the following conditions:
37C for 40 min and 85C for 5 min, followed by a final
cooling to 4C. Sequencing was done by Microsynth
(Balgach, Switzerland). Information on primers used
for sequence analysis is listed in Supplementary 1
(Table 1b).
Results
Quality of the multiplex assay
In the previous studies, the sensitivity and specificity of the
method itself has been proven by us as well as by other
research groups (Garritsen et al. 2009; Thomas et al. 2007;
Xiu-Cheng Fan et al. 2008). Therefore, we only analyzed
several assay quality parameters including call rate and call
probability. For every analyzed locus, these parameters are
automatically calculated by the software MassArray Typer
(Sequenom, Inc.). Assay quality was also assessed by
visual analysis of MALDI-TOF spectrograms. The peak
pattern was quite homogenous, with some slight variations
in peak intensity (Fig. 1a).
Mutational analysis of breast cancer cell lines
and patient samples
Using the MALDI-TOF MS-based 40-plex assay, we
analyzed the mutational status of 40 variants on 21 CAN-
genes in 6 human breast cancer cell lines and tissues of 19
breast cancer patients and 55 healthy controls; no CAN-
gene mutations have been found at the analyzed loci in any
of the cell lines. Regarding the tissue samples, only a single
breast cancer tissue sample showed heterozygosity at locus
c.5834G[A within the ZFYVE26 gene (Zinc finger FYVE
domain-containing gene 26). This heterozygosity could
also be confirmed using a single-plex assay and sequencing
(Fig. 1b, c).
Discussion
Using MALDI-TOF MS 40-plex assay, we evaluated 21
CAN-genes and 40 loci in 6 breast cancer cell lines and in
tissue samples of 19 breast cancer patients and 55 healthy
controls. The frequency of the mutations in our sample
cohort was very low. No mutation was found at the ana-
lyzed loci within the 6 cell lines. Only one breast cancer
patient was found to be heterozygous at one locus within
1242 J Cancer Res Clin Oncol (2011) 137:1239–1244
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the ZFYVE26 gene, which was also confirmed by single-
plex assay and by sequencing. Defects in ZFYVE26 are
known to be the cause of spastic paraplegia autosomal
recessive type 15 (Goizet et al. 2009). However, ZFYVE
seems to play a role in cytokinesis as well. Sagona et al.
showed that depletion of the ZFYVE26 protein in HeLa
cells led to the arrest of cells in cytokinesis (Sagona et al.
2010). A direct association of the gene with breast cancer
has not been reported.
To get an idea whether others had already described
cancer-related mutations at the same positions that we
analyzed in this study, we investigated the COSMIC
(Catalogue of Somatic Mutations in Cancer) database,
Sanger (http://www.sanger.ac.uk/genetics/CGP/cosmic/),
which contains information about previously reported
somatic mutations in cancer. Interestingly, it seems that
most of the CAN-gene loci analyzed in this study have only
been analyzed by Sjo¨blom et al until now, and most of
Fig. 1 Spectrograms of one 40-plex assay and a single-plex assay/
sequencing confirming heterozygosity in ZFYVE26 gene (Zinc finger
FYVE domain-containing gene 26). a Spectrogram of one 40-plex
assay with detailed view in the augmentations a1, a2, and a3. The
dashed lines represent the unextended primers (UEP, followed by
gene name and nucleotide position of the allele) and the respective
alleles. b Single-plex assays for two patients; one homozygote for G
and the other heterozygote for G/A at locus g.chr14:67302874 within
the ZFYVE gene. c Sequencing results for confirmation of hetero-
zygosity at locus g.chr14:67302874 within the ZFYVE gene
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them have not been directly implicated in breast cancer so
far. Only few of the positions, which were included in our
study, have previously been associated with breast cancer,
and mutations at those loci have been found by other
groups. Alsner et al. analyzed the heterogeneity in TP53
mutations in 315 breast cancer patients. Using tumour
material from those patients, they identified 74 TP53
mutations. At position c.488, which is located in the exon 5
of the TP53 gene and was also analyzed in our study, they
found a base exchange from A[G (Alsner et al. 2000).
To conclude, it is widely accepted that the landscapes of
cancer are quite complex (Vogelstein and Kinzler 1993).
Sjo¨blom et al. and Wood et al. showed that just a humble
amount of genes are mutated at higher frequencies, while
most of the genes are mutated at a relatively low frequency
in cancer. Although our study included high-frequency as
well as low-frequency genes/loci, one have to consider as
well the mutational inter- and intra-variations within/
between cancer types, which makes it more difficult to
select the real driver mutations out of a background of
passenger mutations. To really get a conclusion about the
probable value of these CAN-genes for a diagnostic/ther-
apeutic purpose, evaluation of a higher number of CAN-
genes/CAN-gene loci in a larger cohort should be the aim
of further studies.
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